Evaxion Biotech A/S
EVAX5.130USD
+0.210+4.27%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.62BMarket Cap
LossP/E TTM
More Details of Evaxion Biotech A/S Company
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Evaxion Biotech A/S Info
Ticker SymbolEVAX
Company nameEvaxion A/S
IPO dateFeb 05, 2021
CEO- -
Number of employees46
Security typeDepository Receipt
Fiscal year-endFeb 05
AddressDr. Neergaards Vej 5F
CityHOERSHOLM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2970
Phone
Websitehttps://evaxion.ai/
Ticker SymbolEVAX
IPO dateFeb 05, 2021
CEO- -
Company Executives of Evaxion Biotech A/S
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.32%
Merck Sharp & Dohme Corporation
3.06%
Ikarian Capital LLC
1.01%
Boothbay Fund Management, LLC
0.30%
Rhumbline Advisers Ltd. Partnership
0.12%
Other
80.18%
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.32%
Merck Sharp & Dohme Corporation
3.06%
Ikarian Capital LLC
1.01%
Boothbay Fund Management, LLC
0.30%
Rhumbline Advisers Ltd. Partnership
0.12%
Other
80.18%
Shareholder Types
Shareholders
Proportion
Corporation
18.39%
Hedge Fund
1.01%
Investment Advisor/Hedge Fund
0.35%
Investment Advisor
0.12%
Other
80.14%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
24
119.22K
2.61%
--
2025Q3
29
119.22K
2.84%
-1.16K
2025Q2
30
120.38K
3.25%
-17.31K
2025Q1
30
137.73K
1.10%
+68.46K
2024Q4
27
56.73K
8.80%
-56.79K
2024Q3
27
111.11K
9.19%
+19.03K
2024Q2
28
91.47K
7.84%
+14.46K
2024Q1
28
77.00K
2.12%
+54.93K
2023Q4
28
9.74K
18.41%
+6.27K
2023Q3
29
3.47K
3.61%
-551.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Merck & Co Inc
1.21M
19.22%
--
--
Jun 30, 2025
Merck Sharp & Dohme Corporation
242.82K
3.84%
+134.37K
+123.89%
Jan 31, 2025
Ikarian Capital LLC
80.00K
1.27%
--
--
Jun 30, 2025
Boothbay Fund Management, LLC
23.73K
0.38%
--
--
Jun 30, 2025
Rhumbline Advisers Ltd. Partnership
9.44K
0.15%
+7.23K
+327.01%
Jun 30, 2025
GAMMA Investing LLC
3.31K
0.05%
-184.00
-5.27%
Sep 30, 2025
Geode Capital Management, L.L.C.
621.00
0.01%
--
--
Aug 31, 2025
SBI Securities Co., Ltd.
64.00
0%
-2.40K
-97.40%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
Date
Type
Ratio
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Evaxion Biotech A/S?
The top five shareholders of Evaxion Biotech A/S are:
Merck & Co Inc holds 1.21M shares, accounting for 19.22% of the total shares.
Merck Sharp & Dohme Corporation holds 242.82K shares, accounting for 3.84% of the total shares.
Ikarian Capital LLC holds 80.00K shares, accounting for 1.27% of the total shares.
Boothbay Fund Management, LLC holds 23.73K shares, accounting for 0.38% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 9.44K shares, accounting for 0.15% of the total shares.
Merck & Co Inc holds 1.21M shares, accounting for 19.22% of the total shares.
Merck Sharp & Dohme Corporation holds 242.82K shares, accounting for 3.84% of the total shares.
Ikarian Capital LLC holds 80.00K shares, accounting for 1.27% of the total shares.
Boothbay Fund Management, LLC holds 23.73K shares, accounting for 0.38% of the total shares.
Rhumbline Advisers Ltd. Partnership holds 9.44K shares, accounting for 0.15% of the total shares.
What are the top three shareholder types of Evaxion Biotech A/S?
The top three shareholder types of Evaxion Biotech A/S are:
Merck & Co Inc
Merck Sharp & Dohme Corporation
Ikarian Capital LLC
Merck & Co Inc
Merck Sharp & Dohme Corporation
Ikarian Capital LLC
How many institutions hold shares of Evaxion Biotech A/S (EVAX)?
As of 2025Q4, 24 institutions hold shares of Evaxion Biotech A/S, with a combined market value of approximately 119.22K, accounting for 2.61% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.24%.
What is the biggest source of revenue for Evaxion Biotech A/S?
In --, the -- business generated the highest revenue for Evaxion Biotech A/S, amounting to -- and accounting for --% of total revenue.
